...AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) will acquire Perosphere Pharmaceuticals Inc. (Danbury, Conn.) for $50 million up front. AMAG will...
...CEO Bryan Laulicht was a postdoc for Robert Langer, who joined Perosphere's board in January. Perosphere Pharmaceuticals Inc....
...board in January. Perosphere Pharmaceuticals Inc., Danbury, Conn. AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Waltham, Mass. Business: Hematology Sandi Wong AMAG Pharmaceuticals Perosphere...

...Md.) named Patricia Mayer EVP of regulatory affairs. She was VP of regulatory affairs at Perosphere...

...FDA granted Fast Track designation to PER977 from Perosphere for anticoagulant reversal. The company said it...
...the fall. PER977 is a small molecule that binds with heparin and new oral anticoagulants. Perosphere...

...very long time," said James Costin, CMO and VP of clinical and medical affairs at Perosphere...
...is not completely dry for heparin reversal. At least two companies- Portola Pharmaceuticals Inc. and Perosphere-are...
...are specific for reversing heparin anticoagulants and are unlikely to neutralize direct factor Xa inhibitors. Perosphere's...

...Daiichi Sankyo will co-sponsor a Phase I trial evaluating Perosphere's PER977 to reverse the anticoagulant activity...
...prevent recurrent VTE complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Perosphere...
...will not have rights to PER977 under the deal and additional details are not disclosed. Perosphere...

...Date completed: 12/19/11 Type: Venture financing Raised: $1 million Investors: Private investors; company management Note: Perosphere...